Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 3Gastrointestinal 2Thoracic 1Other hematologic neoplasm 1Head & Neck 1Gynecologic 1Dermatologic 1CNS 1Breast 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1Ovarian Neoplasms 1Melanoma 1Gastrointestinal Stromal Tumors 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 81Nivolumab 55Ipilimumab 44Cyclophosphamide 38aldesleukin 26Interleukin-2 25fludarabine 17Temozolomide 17fludarabine phosphate 16trametinib 11dabrafenib 11Radiotherapy 11Biopsy 11avelumab 10Paclitaxel 9spartalizumab 8cemiplimab 8Dacarbazine 8Cisplatin 8Bevacizumab 8sargramostim 7binimetinib 7Fluorouracil 7poly ICLC 6lenvatinib 6epacadostat 6atezolizumab 6Magnetic Resonance Spectroscopy 6Granulocyte-Macrophage Colony-Stimulating Factor 6montanide ISA 51 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × pexidartinib × Dermatologic × Clear all
NCT02452424 2020-03-05

A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors

Daiichi Sankyo

Phase 1/2 Terminated
78 enrolled 19 charts
DermatologicGastrointestinalGynecologicHead & NeckSarcomaThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Melanoma, Ovarian Neoplasms, Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡